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There has been a growth in the prescribing of atypical antipsychotics despite recent concerns with their effectiveness and safety versus first generation antipsychotics. The availability of generic atypical antipsychotics is one way to address cost concerns especially if there are no major differences in outcomes between generic and originator formulations. Market forces do appear to help lower prices if patients have to cover any difference between higher priced generics and originators and the current referenced priced products themselves, which they try to avoid, and companies strive to gain market share. However, this approach may compromise individualising atypical choice if reference classes consist of several atypicals and there are significant co-payment differences between them. 

The objectives of this paper are firstly to assess whether differences in patient co-payment levels between the various atypical antipsychotic formulations do alter the atypical formulation prescribed and/or dispensed in practice in Poland. Secondly, whether market forces in Poland do help drive down generic prices in reality as successive generics are launched. Thirdly, assess the impact of the reduction in reference prices on the overall expenditure of atypicals by the National Health Fund in Poland.

Prescription and reimbursed expenditure data for olanzapine and risperidone was provided by the National Health Fund. There was though no individual patient data. Analysis of the data showed that patient co-payment did appear to impact on the atypical antipsychotic dispensed, with utilisation of olanzapine growing once its co-payment was reduced following the availability of generic olanzapine. The reverse was seen with risperidone, with only limited growth in utilisation when co-payment levels increased. This could be an issue for some patients who are more suited to risperidone than olanzapine, and strategies that help address this are discussed. 

Market forces resulted in a 40% reduction in expenditure/ defined daily dose (DDD limit) of olanzapine and a 77% reduction in expenditure/ DDD of risperidone from 2002 to July 2008. These price reductions did help moderate the growth in atypical expenditure despite appreciable increases in utilisation especially olanzapine. Alongside this, care did not appear to be compromised with a previous retrospective study suggesting generic olanzapine was not associated with increased dosing, side-effects or relapse rates in practice versus the originator. Continued moderation in the growth of atypical expenditure, or even a reduction, is envisaged as more generic formulations are launched despite increasing volumes with further reductions in the reference price/ DDD for both olanzapine and risperidone. 





There has been growing prescribing of atypical antipsychotics in the management of schizophrenia in Europe[1,2,3] matching the growth in the US. As a result, world-wide sales of atypicals are likely to grow well beyond $5bn in 2000[2]. 

The growth in the prescribing of atypical antipsychotics has been driven by meta analyses showing greater efficacy, functional recovery, and lower side-effects especially extra pyramidal side-effects versus typical antipsychotics[1,4]. The improved side-effect profile and improved efficacy of the atypical antipsychotics has also led to improved compliance and persistence[5,6]. However, others were less certain[7]. As a result of a number of studies, NICE in the UK endorsed the prescribing of atypicals in patients experiencing problems with typicals as well as an alternative first line treatment despite significantly higher acquisition costs[1,8]. In 2001, the Italian Reimbursement Agency also agreed to fully reimburse atypicals for approved indications; previously atypicals were only reimbursed for patients intolerant to typicals[2].  

The debate about the quality of evidence has continued though[8] with reviews critical of the differences in efficacy in reality between typical and atypical antipsychotics except for clozapine[9,10] as well as their overall cost-effectiveness[9-11]. This debate has been enhanced with a recent meta analysis critical of many studies as second-generation (atypical) antipsychotics were typically compared with high-potency haloperidol biasing the results[12,13], with only a limited number of studies comparing atypicals with medium-potency first generation antipsychotics[13]. Alongside this greater weight gain, hyperlipidaemia, and Type 2 diabetes is seen with atypical antipsychotics than with first-generation antipsychotic drugs[2,9,10,13]. Others though believe the modest health gains with the atypical antipsychotics sometimes reported in the literature do not adequately reflect the perceptions of patients, clinicians, and carers of the improved quality-of-life with atypicals versus typicals[14].

Despite these controversies, sales of atypical antipsychotics continue to grow[1,2,4] endorsed by psychiatrists and patient associations[8,14] reflecting improvements in quality-of-life in reality[14]. This is likely to remain certainly in the short to medium term reflecting real life experiences even if additional meta analyses are published questioning the actual extent of differences between the first- and second-generation antipsychotics[12,13]. Risperidone and olanzapine are the most commonly prescribed atypical antipsychotics[2,6,14,15] with clozapine reserved in view of its impact on agranulocytosis[9]. In reality there appears limited clinical differences between risperidone and olanzapine with head-to-head studies typically favouring the sponsor’s drug[16]. There is a similar picture when considering the overall costs with each drug[15,17].

As a result of this similarity, initially in Poland ZYPREXA (originator olanzapine) and RISPOLET (originator risperidone) were included in one reference group by the National Health Fund, with the price of RISPOLET setting the reimbursed price on a defined daily dose basis (DDD)[18]  for both products. Patients were required to pay the difference in the price between the reference price and ZYPREXA if they still wished ZYPREXA on top of the basic co-payment per pack (2.5zl in 2002 rising to 3.2zl in 2003 – Table 1). This is because reference priced drugs for schizophrenia in Poland are currently 100% reimbursed, with patients only paying the price differential for a more expensive product if still desired. As a result in 2002, patient co-payment for RISPOLET was 2.5zl for a 20 by 2mg pack and for instance 89.68zl for a 28 by 5mg pack of ZYPREXA (Table 1). 

The atypical antipsychotic reference group was split at the end of November 2003 once the second branded generic olanzapine was launched. The lowest priced olanzapine (branded generic or originator) became the reimbursed reference price for this class, with the lowest price branded generic risperidone (RISSET) establishing the reference price for the risperidone group. There was an additional co-payment if patients still wished the more expensive originator (RISPOLET). This was the case even though there were considerable supply problems with the first branded generic risperidone (RISSET). This resulted in the majority of patients being forced to cover the additional co-payment themselves if their physician still wished to prescribe risperidone rather than olanzapine. This totalled 38.66zl per pack, up from 2.5zl per 20 by 2mg pack (Table 1).

Table 1 – Patient co-payment levels per pack in Polish Zloties for selected formulations of olanzapine and risperidone

Product	2002	November 2003*	December 2004	July 2008
ZYPREXA 28 x 5mg	89.68 zl	87.22 zl	101.29 zl	280.31 zl (100% copayment as removed from the reimbursement list)
ZYPREXA 28 x 10mg	166.70 zl	155.66 zl	202.77 zl	563.40 zl (as for 5mg tablets)
ZOLAFREN (branded generic olanzapine) 30 x 5mg	NA	3.2 zl	3.63 zl	3.2 zl
ZOLAFREN 30 x 10mg	NA	3.2 zl	3.2 zl	3.2 zl
ZALASTA (branded generic olanzapine) 28 x 5mg	NA	NA	3.2 zl	3.2 zl
ZALASTA 28 x 10mg	NA	NA	5.42 zl	3.2 zl
RISPOLET 20 x 2mg	2.5 zl	38.66 zl	38.67 zl	80.25 zl
RISSET (branded generic risperidone) 20 x 2mg		22.94 zl	3.2 zl	3.2 zl
* NB In the beginning of November 2003, all formulations of olanzapine and risperidone were part of one reference price group. Consequently, patient co-payment for risperidone formulations increased until the spilt between risperidone and olanzapine at end November 2003 (reflected in patient co-payments in 2004)

Early published studies in the US have demonstrated that reducing access to psychotropic drugs can increase the use of mental health services among low-income patients with chronic mental illnesses[19]. More recently, Zeber and colleagues demonstrated that among patients receiving healthcare through the Department of Veterans Affairs, even a rise of US$5 per prescription from $2 to $7 for lower-priority patients reduced refill rates for psychiatric drugs by nearly 25%[20]. Recent studies have also shown that non adherence to antipsychotic medication is associated with a higher risk of relapse, rehospitalisations and higher hospital costs[21], as well as accounting for a considerable proportion of inpatient treatment costs of Medicaid (low income) patients with schizophrenia[22]. In addition, we do know from various European studies that patients will adopt cost-reducing behaviour when they can[23,24]. 

Consequently, changes in the co-payment levels between risperidone and olanzapine may adversely impact on outcomes if patients are subsequently forced to choose one class over another, and this class is not best suited to their profile in view of known side-effect differences[9,10]. There appears to be less of an issue if patients are forced to choose one atypical formulation within a class as a recent retrospective survey in Poland of patients prescribed either ZYPREXA, branded generic olanzapine, or both showed similar average effective doses of olanzapine[25].  There was also no appreciable change in olanzapine doses prescribed when formulations were switched. In addition, there no unusual side-effects were seen with branded generic olanzapine formulations compared with the originator. Alongside this, relapse rates appeared similar with either ZYPREXA or branded generic olanzapine, especially when factoring in the considerable length of follow-up in some patients[25]. Finally, to date there were no obvious clinical or patient problems with the various branded generic risperidone formulations available[25].  However, this needs confirming. 





Prescription and reimbursed expenditure data for both risperidone (all formulations) and olanzapine (all formulations) was analysed by one of the authors (MW). The prescription data was provided by the National Health Fund in Poland from 2002 to 2006 in the form of an excel spreadsheet. This contained data on the number of packages dispensed during the year for each drug, the strength of each tablet and their number. There was though no access to individual patient data to match for instance the doses of the different atypicals prescribed and dispensed over time with the indication or adherence and outcomes in practice. Outcomes could include relapse rates and side-effects. However as previously stated, a recently published retrospective survey showed similar average effective doses, similar relapse rates and no unusual side-effect differences between different olanzapine formulations[25]. 

There was though an attempt to compute the number of patients on each formulation. This was derived by calculating the number of DDDs (Defined Daily Dose)[18] for each formulation over the year and dividing this by 365. We recognise that this may well be an over statement; however, this applies equally to all groups.

2006 was chosen as the cut-off date as the market dynamics changed after this with the launch of new atypical antipsychotics. 

The cost analysis is from the payer’s perspective (National Health Fund). The reimbursement limits for both olanzapine and risperidone were calculated by averaging the DDD reimbursement limit for all the products in the reference class in one month; the latest date being July 2008. Polish Zloties are used in this paper as the principal currency (€1 = 3.35zł, and 1US$ = 2.30zl – 1 October 2008). 









Table 2 – Dates different formulations of risperidone and olanzapine became available and the subsequent impact on the reference price limit in Polish Zloties for each class by DDD (Defined Daily Dose)

Year	The olanzapine limit of DDD (average) 	Drug/ formulation setting the reference price limit for olanzapine	The risperidone limit of DDD (average)	Drug/ formulation setting the reference price limit for risperidone
2002	14.63*	RISPOLET (risperidone)	14.63	RISPOLET (risperidone)
from end 11.2003(date of separation) 	10.39*	ZOLAFREN (branded generic olanzapine)	10.42	RISSET (branded generic risperidone)
From 12.2004	9.01*	ZOLAFREN and ZALASTA (branded generic olanzapine)	8.40	RISSET
2008 (July)	8.69*	OLZAPIN (branded generic olanzapine)	3.29	These include:RISSET 2mg, LIOXAM 2mg, RISPERATIO 2, MEPHARIS 2, RYSPOLIT, SPERIDAN 2mg (overall 14 branded generic risperidone. The above currently set the reimbursement limit)  
* The olanzapine limit for the DDD was calculated as an average of the DDD reimbursement limit for all products in the reference class.









The marketing authorisation of branded generic risperidone formulations subsequently impacted on patient co-payment for RISPOLET (Table 1), with competition again helping to drive down the reference price/ DDD for risperidone as more formulations became routinely available (Table 2). The reimbursed price/ DDD in July 2008 was 77% below the originator reference price limit in 2002 (Table 2). 









This difference in patient co-payment levels between olanzapine and risperidone led to olanzapine becoming the atypical antipsychotic of choice for prescriptions from 2002 onwards (Figure 3), with stabilisation in the utilisation of risperidone. The increased utilisation of atypicals helped by off label prescribing for patients with bipolar disease and schizoaffective disorders in addition to those with schizophrenia.





This change in the co-payment for olanzapine also led to increased prescribing of atypicals from 2003 onwards (Figure 3). As a result, increasing National Health Fund expenditure on olanzapine versus risperidone from late 2003 onwards (Figure 4).

Figure 4 – Total NHF (reimbursed) expenditure of the risperidone and olanzapine in Polish Zloties 2003 to 2006


NB The data for 2003 only contains NHF data for the last 5 months 









As seen in Table 1, the manufacturer of ZYPREXA did not appreciably reduce its price to compete once branded generic olanzapine became available setting the reimbursed price for the class. This led to a marked reduction in its market share almost immediately (Figure 5). In addition, the manufacturer temporarily withdrew the product from the market place on 1 July 2005. ZYPREXA has recently been re-launched. However it is not reimbursed leading to high patient co-payments of 280.32zl to 563.40zl per 28 tablet (5 and 10mg) pack (Table 1), which is likely to lead to continued limit prescribing in reality versus branded generic formulations (Figure 5). There could be a similar situation with originator risperidone now that branded generic formulations are routinely available; although this remains to be seen.

The reduction in the expenditure/ DDD of olanzapine (Figure 1) over time as more branded generic formulations are launched resulted in potential savings to the National Health Fund (Table 3). However, overall expenditure still increased (Figure 4) driven by increased utilisation of atypicals (Figure 3). 

Table 3 – Potential savings to the National Health Fund in the initial years following the launch of generic olanzapine

Parameter	2003	2004	2005
Utilisation olanzapine (DDDs)	6 298 630	17 790 430	18 715 826
Gross Value assuming similar expenditure/ DDD as 2002 (PLN)	250 992 356,82 zł	263 646 628,79 zł	333 044 526,16 zł
Gross Value assuming similar expenditure/ DDD as 2004 (PLN)	154 037 020,97 zł	162 415 670,06 zł	205 095 587,30 zł




The apparent similarity in dosing, effectiveness and side-effect rates between olanzapine formulations highlighted in a recently published retrospective review[25] has resulted in the National Health Fund in Poland realising savings from the availability of branded generic olanzapine (Table 3) with each new formulation launched at a lower price to gain market share (Figure 5). These savings should grow as more branded generic olanzapine formulations are launched each at a lower price to gain market share, mirroring the situation with risperidone (Table 2). Alongside this, there also appears to be no apparent clinical or patient problems with various branded generic risperidone formulations available in Poland[25] with the potential for further savings as more formulations are launched. These potential developments should help to continue to moderate the rate of increase in National Health Fund atypical expenditure (Figure 4), or even reduce it, despite significantly increase utilisation from 2002 onwards (Figure 3). However, this remains to be seen.

There are though a number of limitations with the study. These include a ‘before and after’ design without a control group. In addition, there is no access to national patient specific data. As a result, we were unable for instance to match the doses of the different atypicals prescribed and dispensed with the indication, adherence and outcomes in practice. Never-the-less we believe that a number of implications and conclusions can be drawn from the study.

Firstly, we believe these findings and impressions endorse the actions of the National Health Fund to include the different generic atypical formulations and the originator brand in the same reference class, with the market dynamics, including the cost reducing behaviour of patients, leading to lower reimbursed prices (Tables 1 and 2). This is because utilisation of risperidone held up despite significant co-payment differences once generic olanzapine was launched and until generic risperidone became routinely available (Table 1 and Figures 2 and 3). In addition, there have been no apparent clinical or patient problems to date with the various formulations of either generic olanzapine or generic risperidone[25]. The latter confirms the belief that in reality there are only a few instances where generic prescribing and generic substitution is not appropriate and drugs should be prescribed by brand name with ‘no substitution’ indicated[26,27, 28]. This is where differences in formulations could lead to loss of disease control and/ or serious adverse effects such as oral mesalazine and lithium[27, 28]. 

The findings that the extent of patient co-payment significantly influences prescribing and dispensing when choices (Figure 5) are available are in line with previous studies in other European countries demonstrating cost-reducing behaviour among patients[23,24]. Cost-reducing behaviour in the US is also exploited by Managed Care Organisations to steer patients towards lower cost generics or preferred brands associated with significant rebates[29], with typically co-payments of $5, $15, or $35 per prescription respectively for generics, preferred brands and non-preferred brands respectively[29]. This behaviour by patients is acknowledge by brand and branded generic manufacturers in Europe who typically reduce prices to compete as more formulations are launched and patients have to cover the cost themselves of any price differential between the formulation dispensed and the current reference price in addition to any co-payment for the package[27,30-32]. 

We acknowledge we have not analysed whether patients prescribed RISPOLET when RISSET set the reference price for risperidone (Table 1) actually consumed their medication given the sudden increase in co-payment levels and recent findings in the US[20]. We also acknowledge that we have not analysed the impact of nonadherence on patient outcomes following concerns in the US[21,22] since we did not have access to individual patient records for the prescriptions dispensed. However, analysis of prescription data before branded generic olanzapine became available suggests that patients were being dispensed ZYPREXA (Figure 4) despite significantly higher co-payment levels than risperidone (Table 1). This was perhaps because patients were aware in advance of the high co-payment versus risperidone and accepted this to help achieve their desired outcome. This though needs to be fully analysed before any robust statements can be made. In addition, we also acknowledge that we do not know the extent of persistence over time with ZYPREXA, and the subsequent impact on relapses and hospitalisations if patients subsequently developed side-effects on ZYPREXA exacerbating concerns about taking the drug on top of the significant co-payment levels (89.68zl-166.70zl) (Table 1). This before branded generic olanzapine formulations became available with their considerably lower co-payment (Table 1). 

One potential way forward if health authorities want to encourage individual treatment due to concerns with issues such as compliance over time, and the cost of relapses versus the acquisition cost of the drugs[33], could be to impose reimbursement restrictions on more expensive single sourced products in a class. This will provide an alternative strategy to making patients cover the market differences in co-payment levels themselves. This alongside prior authorisation schemes to prevent abuse. This is similar to the current situation in Austria for ambulatory care drugs[34], which has been shown to work in practice[35]. Alternatively, impose price: volume restrictions with payback mechanisms if prescribed volumes are exceeded. These arrangements already exist in a number of European countries such as France, Italy and Portugal[27,36,37] to limit payer exposure to the cost of new and existing drugs, and may be preferable in these situations. 

The launch of ‘ghost products’ influencing reimbursed prices (Table 1) is an issue in Poland. This should now be addressed by the law stating that drugs should be removed from the reimbursement list if there are no stocks in Poland. If not, patient care will be compromised as patients may not be prescribed the optimal drug for them and desired outcomes not attained[21,22,38,39]. 
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